Bonesupport Holding AB (publ) (BONEX.ST)
- Previous Close
284.60 - Open
286.40 - Bid 284.00 x --
- Ask 285.40 x --
- Day's Range
281.80 - 286.40 - 52 Week Range
240.80 - 405.80 - Volume
108,079 - Avg. Volume
183,789 - Market Cap (intraday)
18.783B - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
154.16 - EPS (TTM)
1.85 - Earnings Date Jul 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
434.67
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.
www.bonesupport.comRecent News: BONEX.ST
View MorePerformance Overview: BONEX.ST
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BONEX.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BONEX.ST
View MoreValuation Measures
Market Cap
18.78B
Enterprise Value
18.53B
Trailing P/E
155.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.06
Price/Book (mrq)
25.35
Enterprise Value/Revenue
18.57
Enterprise Value/EBITDA
101.33
Financial Highlights
Profitability and Income Statement
Profit Margin
12.26%
Return on Assets (ttm)
11.16%
Return on Equity (ttm)
18.60%
Revenue (ttm)
997.85M
Net Income Avi to Common (ttm)
122.34M
Diluted EPS (ttm)
1.85
Balance Sheet and Cash Flow
Total Cash (mrq)
267.14M
Total Debt/Equity (mrq)
1.71%
Levered Free Cash Flow (ttm)
-2.98M